Skip to content
EntityQ2313188· pop 12· linked from 398 articles

Becaplermin

Sign in to save

Also known as PDGF B-chain, platelet-derived growth factor BB, PDG109, Platelet-derived growth factor B chain precursor, PDGF-2, c-sis, Regranex, Platelet-derived growth factor beta polypeptide

farmaco

Key facts

Drug.Verifiedfields
changed
Drug.verifiedrevid
458285090
Drug.tradename
Regranex
Drug.MedlinePlus
a699049
Drug.routes_of_administration
Topical
Drug.ATC_prefix
A01
Drug.ATC_suffix
AD08
Drug.ATC_supplemental
,
Drug.legal_US
Rx-only
Drug.CAS_number
165101-51-9
Drug.DrugBank
DB00102
Drug.UNII
1B56C968OA
Drug.ChEMBL
1201556
Drug.ChemSpiderID
none

via Wikipedia infobox

Chemical data

Drug data · ChEMBL

Max clinical phase
Approved
Molecule type
Protein
First approval
1997
Admin. routes
parenteral, topical
Indications
Skin ulcer, diabetic foot, ulcer disease

via ChEMBL · EBI

Wikidata facts

Has use
medication
Show 3 more facts
World Health Organisation international non-proprietary name
becaplermin
medical condition treated
venous ulcer
has characteristic
biopharmaceutical
Sources (4)

via Wikidata · CC0

Article · Italiano

Becaplermin è il principio attivo di indicazione specifica contro le ulcere (specialmente quelle diabetiche neuropatiche), il farmaco non è commercializzato in Italia. Si trova soto forma di pomata ad uso topico con il nome Regranex (Janssen - Cilag) ed è un fattore di crescita ricombinante, il PDGF (Platelet-derived Growth Factor) prodotto in Saccharomyces cerevisae.

Abstract from DBpedia / Wikipedia · CC BY-SA